Clinical Pharmacist–Focused Overview
Definition & Diagnostic Criteria (KDIGO)
AKI = an abrupt decline in renal function occurring over hours to days, diagnosed by any of the following:
- ↑ SCr ≥0.3 mg/dL (26.5 µmol/L) within 48 hours
- ↑ SCr ≥1.5× baseline within 7 days
- Urine output <0.5 mL/kg/h for ≥6 hours
SCr is a late marker—renal injury often precedes measurable rise.
AKI Staging (KDIGO)
| Stage | Serum Creatinine | Urine Output | Clinical Implication |
|---|---|---|---|
| 1 | 1.5–1.9× baseline or ≥0.3 mg/dL ↑ | <0.5 mL/kg/h for 6–12 h | Early injury – intervene |
| 2 | 2.0–2.9× baseline | <0.5 mL/kg/h ≥12 h | High drug toxicity risk |
| 3 | ≥3× baseline or SCr ≥4 mg/dL or RRT | <0.3 mL/kg/h ≥24 h or anuria ≥12 h | ICU, dialysis risk |
Etiology (Pharmacist-Relevant)
Pre-renal (↓ Renal Perfusion – most common)
- Hypovolemia (dehydration, hemorrhage)
- Sepsis, shock
- ACEi/ARBs + NSAIDs + diuretics (“triple whammy”)
Potentially reversible if corrected early
Intrinsic Renal
| Type | Common Causes | Medication Links |
|---|---|---|
| ATN | Ischemia, toxins | Aminoglycosides, vancomycin, contrast |
| AIN | Hypersensitivity | PPIs, β-lactams, NSAIDs |
| GN | Immune-mediated | Biologics, infections |
Post-renal
Always rule out with bladder scan/ultrasound
Medication-Induced AKI (High-Yield List)
| Drug/Class | Mechanism | Pharmacist Action |
|---|---|---|
| NSAIDs | ↓ Prostaglandins → afferent constriction | Avoid in CKD, volume depletion |
| ACEi/ARBs | Efferent dilation | Acceptable mild SCr rise (<30%) |
| Aminoglycosides | Tubular toxicity | Extended-interval dosing |
| Vancomycin | ATN risk (↑ with piptazo) | AUC-guided dosing |
| Contrast media | Ischemic + oxidative | Hydration, risk stratification |
| PPIs | AIN | Stop if unexplained AKI |
Pharmacist Role in AKI Management
Immediate Actions
- Identify baseline SCr and AKI stage
- Review all nephrotoxins
- Adjust or hold renally cleared drugs
- Assess volume status
Dose Adjustment Strategy
| Scenario | Action |
|---|---|
| Rising SCr, non–steady state | Avoid Cockcroft-Gault |
| Oliguric/anuric | Assume minimal clearance |
| AKI + sepsis | Dose for expanded Vd, not CrCl |
| Recovery phase | Re-escalate doses cautiously |
Renal function during AKI is dynamic → daily reassessment required.
AKI & Drug Dosing Pitfalls
- SCr underestimates AKI in elderly/ICU
- Renally cleared drugs may accumulate before SCr rises
- Over-reduction may cause subtherapeutic exposure (e.g., β-lactams)
- RRT initiation changes drug clearance abruptly
Indications for Renal Replacement Therapy (AEIOU)
| A | Acidosis (refractory) |
|---|---|
| E | Electrolytes (K⁺, severe) |
| I | Intoxications (dialyzable toxins) |
| O | Overload (pulmonary edema) |
| U | Uremic complications |
Dialysis ≠ kidney recovery.
Monitoring Parameters (Pharmacist Checklist)
| Parameter | Why It Matters |
|---|---|
| SCr & UOP trends | AKI progression |
| Electrolytes | K⁺, PO₄, Mg²⁺ |
| Acid–base status | Metabolic acidosis |
| Drug levels | Vancomycin, aminoglycosides |
| Fluid balance | Avoid overload |
AKI in Special Populations
ICU
- Non-oliguric AKI common
- Augmented renal clearance may coexist early
- CRRT dosing required
Oncology
Elderly
- Low muscle mass masks SCr rise
- Higher risk of drug accumulation
Clinical Pearls for Hospital Pharmacists
- AKI is a clinical diagnosis, not a number
- Early nephrotoxin cessation prevents progression
- A mild creatinine rise may signal major GFR loss
- Dose changes should be temporary & reassessed daily
- Preventing AKI is easier than treating it